Hao Guo

Hao Guo

Auto-generated profile, based on publicly available information

Hao Guo

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, 361102, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2020 in Science
Verified
Journal Article
Closed access
HGHao Guo
Hao Guo
WCWei-Chun Chou
Wei-Chun Chou
YLYunjia Lai
Yunjia Lai
KLKaixin Liang
Kaixin Liang
JTJason W. Tam
Jason W. Tam
JTJenny P. Y. Ting
Jenny P. Y. Ting
Radioprotective bacteria: A common symptom of radiation treatment for cancer is gastrointestinal disruption. The damage caused can become so severe and debilitating that it interrupts treatment. Guo et al. noticed that mice surviving experimental radiation exposure had distinctive taxonomic representation in their gut microbiota. A similar correlation was also observed in a small group of human subjects. Further experiments in mice revealed that some strains of bacteria produced high levels of short-chain fatty acids, which seemed to be dampening inflammatory responses and alleviating the damage caused by reactive oxygen species released by the radiation. A metabolomics analysis also implicated a role for tryptophan metabolic pathways in radiation survivorship. Science , this issue p. eaay9097

27 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WCWei-Chun Chou
Wei-Chun Chou
ZGZengli Guo
Zengli Guo
HGHao Guo
Hao Guo
LCLiang Chen
Liang Chen
GZGe Zhang
Ge Zhang
JTJenny P.-Y. Ting
Jenny P.-Y. Ting

5 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WBW. June Brickey
W. June Brickey
DCDavid L. Caudell
David L. Caudell
MAMacintyre Andrew
Macintyre Andrew
JOJohn D. Olson
John D. Olson
YDYanwan Dai
Yanwan Dai
JTJenny P. Y. Ting
Jenny P. Y. Ting
Thrombocytopenia, hemorrhage, anemia, and infection are life-threatening issues following accidental or intentional radiation exposure. Since few therapeutics are available, safe and efficacious small molecules to mitigate radiation-induced injury need to be developed. Our previous study showed the synthetic TLR2/TLR6 ligand fibroblast stimulating lipopeptide (FSL-1) prolonged survival and provided MyD88-dependent mitigation of hematopoietic acute radiation syndrome (H-ARS) in mice. Although mice and humans differ in TLR number, expression, and function, nonhuman primate (NHP) TLRs are like those of humans; therefore, studying both animal models is critical for drug development. The objectives of this study were to determine the efficacy of FSL-1 on hematopoietic recovery in small and large animal models subjected to sublethal total body irradiation and investigate its mechanism of action. In mice, we demonstrate a lack of adverse effects, an easy route of delivery (subcutaneous) and efficacy in promoting hematopoietic progenitor cell proliferation by FSL-1. NHP given radiation, followed a day later with a single subcutaneous administration of FSL-1, displayed no adversity but showed elevated hematopoietic cells. Our analyses revealed that FSL-1 promoted red blood cell development and induced soluble effectors following radiation exposure. Cytologic analysis of bone marrow aspirates revealed a striking enhancement of mononuclear progenitor cells in FSL-1-treated NHP. Combining the efficacy of FSL-1 in promoting hematopoietic cell recovery with the lack of adverse effects induced by a single administration supports the application of FSL-1 as a viable countermeasure against H-ARS.

1 October 2025 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
NCNing Chen
Ning Chen
MZMengdan Zhang
Mengdan Zhang
BSBaohong Shi
Baohong Shi
XLXiumei Luo
Xiumei Luo
RHRui Huang
Rui Huang
YLYuejun Liu
Yuejun Liu
As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, Tirzepatide (TZP) is a recently approved medication for treating type 2 diabetes mellitus (T2DM) and obesity; however, the effect of TZP in bone remodeling remains unclear. 1. The effect of Tirzepatide on osteoblasts and osteoclasts was observed by inducing differentiation of bone marrow mesenchymal cells (BMSCs) in vitro. 2. Db/db mice were used as a pathological model to investigate the role of TZP on bone metabolism. After TZP intervention, the feces in the intestinal tract of mice were collected for 16s rRNA gene sequencing to select the candidate gut microbiota most related to bone mass, and the effects of gut microbiota on bone metabolism were verified through subsequent microbiota supplementation experiments. 3. Metabolomics was used to analyze the difference of fecal metabolites between mice with the candidate microbiota supplement and those without, and the effect of candidate metabolites on bone metabolism was verified by the in vitro intervention of differential metabolites in BMSCs induction differentiation experiments. We found that TZP intervention resulted in a significant decrease in bone mass accrual in vivo. TZP was not indispensable to the differentiation of osteoblasts and osteoclasts in vitro. Bone and fat homeostasis were modulated by gut microbiota. We further demonstrated that the biodiversity of the gut microbiota in db/db mice was strikingly altered after TZP treatment. Lachnospiraceae, a key pro-osteogenic component of gut microbiota was significantly reduced. As a main metabolite of Lachnospiraceae, evodiamine played a role in suppressing osteoclastogenesis in vitro. Based on this, the transplantation of the Lachnospiraceae effectively ameliorated bone loss that was seen in db/db mice due to TZP treatment. TZP administration leads to bone loss in the context of diabetes and obesity, and targeting the composition of gut microbiota may provide a potential way to protect bone health in type 2 diabetic patients treating with TZP. This study indicates that TZP has a negative impact on bone mass, suggesting that clinical attention should be paid to the risk of further decline in bone mass after Tirzepatide treatment, and it is necessary to follow up on their bone metabolism. Additionally, the gut microbiota plays an important role in bone metabolism regulation, and supplementing with certain probiotics may have a preventive effect on bone mass reduction associated with TZP treatment. Our research provides a reference for the prevention and treatment of drug-related osteoporosis in patients with T2DM in the future.

14 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WCWei-Chun Chou
Wei-Chun Chou
ZGZengli Guo
Zengli Guo
HGHao Guo
Hao Guo
LCLiang Chen
Liang Chen
GZGe Zhang
Ge Zhang
JTJenny P.-Y. Ting
Jenny P.-Y. Ting

19 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
WCWei-Chun Chou
Wei-Chun Chou
ZGZengli Guo
Zengli Guo
HGHao Guo
Hao Guo
LCLiang Chen
Liang Chen
GZGe Zhang
Ge Zhang
JTJenny P.-Y. Ting
Jenny P.-Y. Ting